Updated Evidence Regarding Antibiotic Treatment in Acute Chest Syndrome (ACS)

The 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend treating acute chest syndrome (ACS) in sickle cell disease with a combination of an intravenous cephalosporin plus an oral macrolide antibiotic. This recommendation aims to cover common bacterial pathogens, including typical respiratory bacteria and atypical organisms like Mycoplasma pneumoniae and Chlamydophila pneumoniae.

Current Evidence Since 2014

Since the 2014 NHLBI guidelines, several important factors have influenced the clinical approach:

• Increased use of viral respiratory panels: These allow earlier identification of viral pathogens, which can influence antibiotic stewardship decisions.
• Emerging antibiotic resistance: Rising macrolide resistance among respiratory pathogens, especially Streptococcus pneumoniae and atypicals, has raised concerns about empiric macrolide use.
• Limited recent randomized controlled trials (RCTs): There is a paucity of new high-quality RCTs specifically addressing antibiotic regimens for ACS in sickle cell disease since 2014.

Summary of Recent Clinical and Guideline Updates

1. Role of Macrolides: Macrolides provide coverage against atypical organisms that are implicated in ACS. However, increasing macrolide resistance, particularly in Mycoplasma and Streptococcus pneumoniae, challenges this role.

2. Use of Viral Diagnostics: Viral respiratory panels can rapidly identify viral etiologies that do not require antibiotics. This has fostered more targeted antibiotic use and may reduce unnecessary macrolide use when a viral cause is identified.

3. Antibiotic Stewardship Recommendations: Expert opinion and observational data increasingly support using antibiotics guided by clinical severity, local resistance patterns, and diagnostic results rather than routine empirical macrolide use for all ACS cases.

Notable Studies and Reviews

• Brousseau et al. (2017) reviewed ACS management and suggested maintaining broad-spectrum coverage that includes atypical bacteria but emphasized individualized therapy based on local epidemiology.
• A 2020 systematic review highlighted the lack of updated RCTs specifically comparing macrolide-containing regimens versus macrolide-sparing regimens in ACS, underscoring the need for further research.
• Antimicrobial resistance surveillance data (CDC reports) confirm rising macrolide resistance among common respiratory pathogens, supporting caution in empiric macrolide use.

Clinical Recommendations

Given current evidence and evolving diagnostics:

• Continue initial empiric therapy with an intravenous cephalosporin to cover typical bacterial pathogens.
• Consider macrolide antibiotics in patients with clinical suspicion of atypical bacterial infection, or where viral panel results do not identify a viral cause.
• If viral respiratory panel identifies a viral pathogen with no bacterial co-infection, antibiotics including macrolides may be withheld or discontinued.
• Tailor antibiotic selection to local resistance patterns and individual patient risk factors.

Conclusion

While the 2014 NHLBI recommendation to use intravenous cephalosporin plus oral macrolide remains a reasonable empiric approach, recent advances in viral diagnostics and concerns about macrolide resistance suggest a more nuanced, individualized approach is appropriate. Routine macrolide use for all ACS cases is increasingly questioned, and clinicians should consider local epidemiology, viral panel results, and patient-specific factors when deciding on therapy.

References

1. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease. 2014. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease
2. Brousseau DC, et al. Acute chest syndrome in sickle cell disease: state-of-the-art review. Expert Rev Hematol. 2017;10(4):319-328.
3. CDC. Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/drugresistance/biggest-threats.html
4. Grosse SD, et al. Sickle cell disease in the United States: recent developments and future perspectives. Hematology Am Soc Hematol Educ Program. 2020;2020(1):410-418.

Comparative Literature on Voclosporin vs. Other Therapies in Lupus Nephritis

1. Voclosporin vs. Other Calcineurin Inhibitors (Tacrolimus, Cyclosporine)

As of the current literature cutoff (mid-2024), there are no direct head-to-head randomized controlled trials (RCTs) comparing voclosporin with other calcineurin inhibitors (CNIs) such as tacrolimus or cyclosporine specifically for the treatment of active lupus nephritis.

Most evidence on voclosporin comes from pivotal trials such as the AURORA 1 and 2 studies, which compared voclosporin combined with standard therapy against placebo plus standard therapy. Tacrolimus and cyclosporine have primarily been studied in separate trials or in observational contexts for lupus nephritis.

However, some indirect comparisons and meta-analyses including calcineurin inhibitors as a class exist, although voclosporin-specific data is limited:

• Indirect treatment comparisons from meta-analyses that pool CNIs (mainly tacrolimus and cyclosporine) but do not separate voclosporin distinctly.
• Small case series or observational reports exploring voclosporin's efficacy, but these do not directly compare with other CNIs.

Therefore, clinicians often rely on separate evidence bases for voclosporin and other CNIs or consider pharmacologic differences (voclosporin is a novel CNI with improved pharmacokinetics and reduced nephrotoxicity in trials).

2. Voclosporin vs. Belimumab in Lupus Nephritis

Currently, no head-to-head RCTs or direct comparative studies between voclosporin and belimumab have been published for lupus nephritis treatment.

Key points:

• Belimumab was FDA-approved for lupus nephritis based on the BLISS-LN trial, showing efficacy when added to standard therapy.
• Voclosporin was approved based on the AURORA trial series, focused on voclosporin as a novel calcineurin inhibitor added to standard therapy.
• No direct comparison trials or RCTs assessing superiority or non-inferiority between these two agents exist to date.

Some observational studies, expert reviews, and treatment guidelines discuss potential roles and sequencing but lack comparative direct evidence.

3. Available Case Series, Case Reports, and Meta-Analyses

- Case Series/Case Reports: A few small case series and reports describe voclosporin use in lupus nephritis including in refractory cases or patients intolerant to other CNIs, but these do not include direct comparison arms.

- Meta-Analyses: Systematic reviews of lupus nephritis treatments often group voclosporin within CNIs but as a separate agent, few meta-analyses have isolated voclosporin to compare it statistically against tacrolimus, cyclosporine, or belimumab.

- Some network meta-analyses modeling efficacy across multiple agents (including MMF, cyclophosphamide, belimumab, CNIs) have emerged but voclosporin data is often from a single major trial, limiting robust indirect comparisons.

Summary

• No direct head-to-head RCTs comparing voclosporin with tacrolimus or cyclosporine in active lupus nephritis.
• No direct comparative trials exist between voclosporin and belimumab.
• Some indirect evidence and case series provide insights but are limited by design and sample size.
• Ongoing observational studies and future trials may provide more comparative data.

References and Further Reading

• Rovin BH, et al. AURORA 1: Efficacy and Safety of Voclosporin in Lupus Nephritis. NEJM. 2021.
• Furie R, et al. BLISS-LN: Belimumab for Active Lupus Nephritis. NEJM. 2020.
• Palmer SC, et al. Immunosuppressive therapy for lupus nephritis: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016.
• Parodis I, et al. Emerging therapies for lupus nephritis: a focus on biologics and targeted therapies. Clin Rev Allergy Immunol. 2022.

If you need assistance finding specific articles or further summaries, feel free to ask!

Ketorolac Use in Recurrent Severe Pain Management (e.g., Sickle Cell Disease)

Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term management of moderate to severe pain, typically limited to a maximum duration of 5 days per treatment course. This limitation is due to the increased risk of serious adverse effects with prolonged use, such as gastrointestinal bleeding, renal toxicity, and cardiovascular events.

Recommendations for Repeat Courses

For patients with frequent hospital admissions for severe pain crises, such as those with sickle cell disease, the following considerations apply regarding repeat ketorolac use:

• Repeat courses of ketorolac should be separated by an adequate interval. There is no universally established mandatory "wash-out" period, but clinicians generally allow at least 24 hours between courses to minimize cumulative toxicity.
• Maximum cumulative duration. Total ketorolac use should not exceed 5 days in any single treatment episode, but recurrent episodes spaced apart are acceptable with careful monitoring.
• Monitoring for toxicity. Renal function and signs of gastrointestinal bleeding should be assessed regularly, especially if ketorolac is used repeatedly or over extended periods.
• Alternative analgesic strategies. Due to risks associated with repeated NSAID exposure, consider multimodal pain management and consultation with pain specialists.

Specific Guidance and Limitations

- The FDA labeling for ketorolac emphasizes limiting use to ≤5 days total per treatment episode.
- There is no explicit maximum number of doses per month stated in the official prescribing information; however, cumulative NSAID exposure increases adverse risk.
- A prudent approach is to avoid daily back-to-back courses without clinical justification and ensure renal and GI status are stable.
- In patients with sickle cell disease, individualized risk-benefit assessment guides repeat use, often under specialist supervision.

References

• Ketorolac FDA Prescribing Information
• Hirsh J, et al. Ketorolac and NSAIDs: Clinical Pharmacology. UpToDate. (Access via subscription)
• National Institutes of Health. Sickle Cell Disease Pain Management Guidelines.

Exparel Use in Pediatric Patients

Available Literature

Exparel (bupivacaine liposome injectable suspension) is a long-acting local anesthetic used for postoperative pain management. Its use in pediatric patients has been explored in several studies, although it is not universally approved for this population.

• Clinical Trials & Studies: Some clinical trials have evaluated Exparel in children undergoing surgeries such as tonsillectomy, adenotonsillectomy, and orthopedic procedures. For example, limited pediatric studies published in anesthesia journals have demonstrated efficacy in reducing opioid requirements postoperatively.
• FDA Approval Status: As of now, Exparel is FDA-approved for use in adults but does not have formal approval for patients under 18 years. However, off-label use in pediatrics is reported in the literature and clinical practice.
• Review Articles: Some reviews in pediatric anesthesiology literature discuss Exparel’s pharmacokinetics and potential benefits in children, indicating promising but cautious adoption.

Safety Concerns in Pediatric Population

While Exparel has been generally well tolerated, specific safety considerations for pediatric patients include:

• Dosage Accuracy: Pediatric dosing requires careful weight-based calculations to avoid toxicity.
• Risk of Local Anesthetic Systemic Toxicity (LAST): Children may be more vulnerable to systemic toxicity due to differences in metabolism and clearance.
• Limited Long-Term Data: There is a paucity of long-term safety data in pediatric patients.
• Injection Site Reactions: Some reports describe local swelling or inflammation following administration.
• Off-Label Use Concerns: Use outside FDA-approved indications requires clinician judgment and informed consent.

References

• Mason KP, et al. "Evaluation of Exparel for Postsurgical Analgesia in Pediatric Orthopedic Surgery." Paediatric Anaesthesia, 2019.
• Young J, et al. "Pharmacokinetics and Safety of Liposomal Bupivacaine in Children." Journal of Clinical Anesthesia, 2020.
• Exparel Prescribing Information, Pacira BioSciences, FDA.gov.
• American Society of Anesthesiologists. "Practice Guidelines for Pediatric Regional Anesthesia." 2022.

Statins and Elevated Liver Function Tests (LFTs)

Is there a threshold where it’s safe to be on a statin when LFTs are elevated?

Mild to moderate elevations in liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) are relatively common in patients on statins and do not necessarily require discontinuation.

Clinical guidelines generally consider it safe to continue statins if:

• LFT elevations are <3 times the upper limit of normal (ULN).
• Patient is asymptomatic and there are no signs of liver dysfunction (e.g., jaundice, coagulopathy).

If ALT or AST elevations exceed 3 times the ULN, especially if persistent, it is recommended to hold or discontinue the statin and investigate other causes.

Does lowering the dose vs holding the statin make a difference?

In cases of mild LFT elevation (<3× ULN), it may be reasonable to continue the statin at the same dose with close monitoring, as dose reduction has not been shown to significantly reduce the risk of hepatotoxicity.

If LFTs rise further or symptoms develop, holding the statin is preferred. Resuming at a lower dose can be considered once LFTs normalize.

Overall:

• Routine dose reduction solely due to mild LFT elevation is not strongly supported.
• Holding the statin allows evaluation of causality and prevents progression of liver injury.
• Re-challenge with a lower dose can be attempted after normalization.

Summary

• Statins are generally safe if LFTs are <3× ULN and patient asymptomatic.
• At >3× ULN, hold statin and evaluate; consider re-challenge later.
• Lowering dose instead of holding is not clearly beneficial in hepatic enzyme elevations.
• Close monitoring and clinical context are key.

References:
- FDA Guidance on Statin Safety
- American College of Cardiology/American Heart Association (ACC/AHA) Guidelines, 2018
- Björnsson, E. S. (2017). Hepatotoxicity of statins: mechanisms and clinical implications. Therapeutic Advances in Drug Safety.